Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.

Authors: Penning, Trevor M

Published In Expert Opin Ther Pat, (2017 Dec)

Abstract: AKR1C3 is a drug target in hormonal and hormonal independent malignancies and acts as a major peripheral 17β-hydroxysteroid dehydrogenase to yield the potent androgens testosterone and dihydrotestosterone, and as a prostaglandin (PG) F synthase to produce proliferative ligands for the PG FP receptor. AKR1C3 inhibitors may have distinct advantages over existing therapeutics for the treatment of castration resistant prostate cancer, breast cancer and acute myeloid leukemia. Area covered: This article reviews the patent literature on AKR1C3 inhibitors using SciFinder which identified inhibitors in the following chemical classes: N-phenylsulfonyl-indoles, N-(benzimidazoylylcarbonyl)- N-(indoylylcarbonyl)- and N-(pyridinepyrrolyl)- piperidines, N-benzimidazoles and N-benzindoles, repurposed nonsteroidal antiinflammatory drugs (indole acetic acids, N-phenylanthranilates and aryl propionic acids), isoquinolines, and nitrogen and sulfur substituted estrenes. The article evaluates inhibitor AKR potency, specificity, efficacy in cell-based and xenograft models and clinical utility. The advantage of bifunctional compounds that either competitively inhibit AKR1C3 and block its androgen receptor (AR) coactivator function or act as AKR1C3 inhibitors and direct acting AR antagonists are discussed. Expert opinion: A large number of potent and selective inhibitors of AKR1C3 have been described however, preclinical optimization, is required before their benefit in human disease can be assessed.

PubMed ID: 28895472 Exiting the NIEHS site

MeSH Terms: Aldo-Keto Reductase Family 1 Member C3/antagonists & inhibitors*; Animals; Antineoplastic Agents/pharmacology*; Breast Neoplasms/drug therapy; Breast Neoplasms/pathology; Drug Design; Enzyme Inhibitors/pharmacology*; Female; Humans; Leukemia, Myeloid, Acute/drug therapy; Leukemia, Myeloid, Acute/pathology; Male; Patents as Topic; Prostatic Neoplasms, Castration-Resistant/drug therapy; Prostatic Neoplasms, Castration-Resistant/pathology

to Top